actin-binding motif is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
==== Cation attachment ==== In the process of cation attachment, cations (typically H+ or Na+) attach themselves to analyte molecules; the desorption of the cation attachment (e.g., MNa+) can then be realized through the emitter heating and high field. The ionization of more polar organic molecules (e.g., ones with aliphatic hydroxyl or amino groups) in FD-MS typically go through this mechanism.
=== Leak === On September 19, the Half-Life 2 source code was obtained by a German hacker, Axel Gembe, who had infiltrated Valve's internal network months earlier. According to Gembe, he shared it with another person, who leaked the code online in early October. Fans soon compiled a playable version of Half-Life 2, revealing how unfinished it was. The leaks damaged morale at Valve and slowed development. Fans also provided Valve with the details of people involved in the leaks. In March 2004, Gembe contacted Newell, saying he was a fan and had not acted maliciously. Newell worked with the FBI to invite Gembe to a fake job interview, planning to have him arrested in the United States; however, police arrested him in Germany. In November 2006, Gembe was sentenced to two years' probation. Valve implemented new policies to protect against leaks, such as requiring journalists to attend their office to play it before release.
Affinity towards An(III) over Ln(III) Good An(III) back-extraction to enable solvent recycling Good solubility in a proper diluent CHON compliance to reduce secondary waste Fast complexation kinetics Hydrodynamic stability to prevent third phase and precipitates formation during extraction process Chemical and radiolytic stability to prevent solvent degradation Research on advanced reprocessing of spent nuclear fuel moves on by developing process optimization studies and designing new potential lipophilic and hydrophilic extracting agents that fulfill these industrial requirements.
Sources: en.wikipedia.org
Douglas Hart – bass (1984–1991) Murray Dalglish – drums (1984) Bobby Gillespie – drums (1984–1986, 2017) John Moore – rhythm guitar (1986–1987, 2012), drums (1985–1986) Martin Hewes – drums (1986) James Pinker – drums (1986) Dave Evans – rhythm guitar (1987–1989) Richard Thomas – drums (1988–1990) Ben Lurie – rhythm guitar, bass, organ (1989–1998) Steve Monti – drums (1990–1995) Matthew Parkin – bass (1992) Barry Blackler – drums (1992) Nick Sanderson – drums (1993–1998; died 2008) Lincoln Fong – bass (1994–1995) Geoff Donkin – drums (1998) Phil King – bass, rhythm guitar (1998, 2007–2015) Loz Colbert – drums (2007–2008) Brian Young – drums (2012–2021)
Bacterial alginates are useful for the production of micro- or nanostructures suitable for medical applications. Sodium alginate (NaC6H7O6) is the sodium salt of alginic acid. Sodium alginate is a gum. Potassium alginate (KC6H7O6) is the potassium salt of alginic acid. Calcium alginate (CaC12H14O12) is the calcium salt of alginic acid. It is made by replacing the sodium ion in sodium alginate with a calcium ion (ion exchange).
== Stanford Research Institute == In 1962, Finnigan and one of his coworkers, physicist and nuclear engineer P. Michael Uthe Jr., left Livermore to work for the Stanford Research Institute (SRI) in Palo Alto, California. Finnigan was hired to establish a process controls group in SRI's control systems lab. SRI did contract research projects for both business and the military. One of the projects underway at SRI, led by Kenneth R. Shoulders, was developing a quadrupole mass spectrometer. Finnigan saw the potential for using the quadrupole broadly as a detector for instrumentation and process-control, and began trying to find support for its development and commercialization.
Pharmacological stimulation of arteriogenesis, important for the treatment of arterial occlusive diseases, seems feasible with NO donors." Kolibash's 1982 study of the effect of collaterals on rest and stress myocardial perfusion, left ventricular function, and myocardial infarction prevention was most influential in turning the tide of professional opinion toward acknowledging the impact of these vessels on the jeopardized heart. In 91 patients examined by angiography, 90% of which had exertional angina, Kolibash discovered 110 occluded LAD and RCA vessels, 101 of which showed evidence of collateral vessels in their proximal areas. Kolibash divided these 101 proximal areas into two groups: those with normal perfusion at rest (43) and those with abnormal perfusion at rest (58). Wall motion abnormalities were significantly less evident in areas with normal rest perfusion—only 35% of these areas showed decreased segment shortening. By comparison, 72% of areas with abnormal rest perfusion showed decreased segment shortening. Infarctions also occurred less often in the normals than in the abnormals (12% vs. 62%). Examining four variables—rest perfusion, stress perfusion, wall motion abnormalities, and EKG evidence of MI, Kolibash found that 86% of the variables were normal in the normal perfusion group and 81% of the variables were abnormal in the abnormal perfusion group.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.